ATEC Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
Alphatec Holdings (ATEC) announced the closing of its public offering of 13,142,855 common shares, raising approximately $115 million at a price of $8.75 per share. This includes the full exercise of underwriters' options for an additional 1,714,285 shares. The offering was managed by Morgan Stanley and Cowen, among others. The shares were offered under a previously declared effective shelf registration statement with the SEC. ATEC aims to innovate spine surgery through its subsidiaries, focusing on safe and effective treatment solutions.
- Successfully raised approximately $115 million from the public offering of 13,142,855 shares.
- Increased financial resources may support further innovation and development in spine surgery.
- None.
CARLSBAD, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 13,142,855 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,714,285 additional shares of common stock, at a public offering price of
Morgan Stanley and Cowen acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering, with Lake Street Capital Markets and Northland Capital Markets acting as co-managers.
The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-241677) previously filed with and declared effective by the Securities and Exchange Commission. The offering was made by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed previously with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying base prospectus will be filed with the SEC and available on the SEC’s website thereafter, and, when available, may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by e-mail at prospectus@morganstanley.com or Cowen and Company, LLC, at c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ATEC
Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine’s various pathologies and achieve the goals of spine surgery. Alphatec’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Company Contact:
Jeff Black
Chief Financial Officer
investorrelations@atecspine.com
Investor/Media Contact:
Tina Jacobsen
Investor Relations
(760) 494-6790
investorrelations@atecspine.com
FAQ
What is the purpose of Alphatec's recent public offering of shares?
How many shares did Alphatec offer in its recent public offering?
What was the price per share in Alphatec's recent offering?
Who managed Alphatec's public offering?
What are the expected proceeds from Alphatec's public offering?
